ストックスクリーナーアプリを入手
3.30
11.41%
-0.425
アフターアワーズ：
3.45
0.15
+4.55%
前日終値:
$3.725
開ける：
$3.73
24時間の取引高:
268.64K
Relative Volume:
2.52
時価総額：
$30.88M
収益：
-
当期純損益:
$-16.76M
株価収益率:
-41.25
EPS:
-0.08
ネットキャッシュフロー:
$-132.97M
1週間 パフォーマンス:
-38.14%
1か月 パフォーマンス:
-48.74%
6か月 パフォーマンス:
-80.22%
1年 パフォーマンス:
-90.43%
1日の値動き範囲:
$3.1601
$3.75
1週間の範囲:
$3.1601
$5.50
52週間の値動き範囲:
$3.1601
$36.00
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
XFOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.30 | 30.88M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
HC Wainwright Raises X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $7.00 - Defense World
Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
X4 Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
XFOR: HC Wainwright Raises Price Target for X4 Pharmaceuticals | - GuruFocus
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - Quantisnow
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript - Insider Monkey
X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ... - Yahoo Finance
Layoff Tracker: BMS Closes Manufacturing Plant, Arvinas Axes One-Third of Staff - BioSpace
X4 Pharmaceuticals targets $1-2B U.S. market for mavorixafor in chronic neutropenia - MSN
X4 Pharmaceuticals Q1 2025 slides: XOLREMDI launch drives revenue beat amid pipeline progress - Investing.com India
Fierce Biotech Layoff Tracker 2025: Arvinas lays off a third of staffers; Entrada cuts 20% of workforce - Fierce Biotech
Earnings call transcript: X4 Pharmaceuticals beats Q1 2025 EPS expectations - Investing.com Australia
Earnings call transcript: X4 Pharmaceuticals beats Q1 2025 EPS expectations By Investing.com - Investing.com UK
X4 Pharmaceuticals, Inc SEC 10-Q Report - TradingView
X4 Pharmaceuticals (XFOR) Posts Strong Q1 Results with Notable C - GuruFocus
X4 Pharmaceuticals: Q1 Earnings Snapshot - San Antonio Express-News
X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings: EPS of $0.04 Bea - GuruFocus
XFOR Q1 Revenue Surges to $28.8 Million, Spotlighting Significan - GuruFocus
X4 Pharmaceuticals Full Enrollment On Track For 3Q Or 4Q 2025 And Top-Line Data In 2H 2026 - marketscreener.com
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025 - Insider Monkey
X Marks the Spot: Challenges for Therapeutic Target Engagement in DBS - Psychiatric Times
Market Recap: X4 Pharmaceuticals Inc (XFOR)’s Positive Momentum, Closing at 0.19 - DWinneX
The Potential Rise in the Price of X4 Pharmaceuticals Inc (XFOR) following insiders activity - knoxdaily.com
Top 3 Health Care Stocks That May Rocket Higher In April - Benzinga
A look into X4 Pharmaceuticals Inc (XFOR)’s deeper side - Sete News
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 - marketscreener.com
X4 Pharmaceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
X4 Pharmaceuticals To Enact 1-for-30 Reverse Stock Split, Effective April 28, 2025 - Nasdaq
X4 Pharmaceuticals announces reverse stock split - Investing.com
X4 Pharmaceuticals Announces Reverse Stock Split - The Manila Times
X4 Pharmaceuticals Unveils Major 1-for-30 Stock Restructuring: Critical Nasdaq Compliance Plan Revealed - Stock Titan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA - Quantisnow
Evaluating XFOR’s financial ratios for a profitable investment - uspostnews.com
X4 Pharmaceuticals Inc [XFOR] Investment Guide: What You Need to Know - knoxdaily.com
SEC Form DEFA14A filed by Kiniksa Pharmaceuticals International plc - Quantisnow
The top 20 pharma companies by 2024 revenue - Fierce Pharma
Top 10 pharma companies in India by market cap [2025] - Forbes India
Analyzing X4 Pharmaceuticals (NASDAQ:XFOR) & Pluri (NASDAQ:PLUR) - Defense World
Ionis to hold first quarter 2025 financial results webcast - Quantisnow
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Yahoo Finance
Director Foehr Matthew W exercised 20,786 shares at a strike of $8.00, increasing direct ownership by 19% to 132,036 units (SEC Form 4) - Quantisnow
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA” - Yahoo Finance
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - marketscreener.com
SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow
X4 Pharmaceuticals Expands Board of Directors Through Appointment of Biopharmaceutical Industry Veteran Alison Lawton - MarketScreener
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - BioSpace
Now Pharma Inc looks for cure as Trump delivers dose of anxiety - The Economic Times
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):